CXCL10 and autoimmune disease: It is important to note, however, that although CXCL10 has been proven to be a useful biomarker of type I interferonopathies in the past1, it is also known to be upregulated in several other autoimmune disorders, so this upregulation is not necessarily specific to type I interferonopathies38.